1、同济大学附属妇产科医院转化医学研究中心，副研究员
2、担任cellular oncology等杂志审稿人
3、日本癌症协会（JCA）会员
4、美国癌症协会（AACR）会员
1. Associate Researcher, Translational Medicine Research Center, Obstetrics and Gynecology Hospital, Tongji University
2. Act as a reviewer for journals, including Cellular Oncology
3. Member of the Japan Cancer Association (JCA)
4. Member of the American Association for Cancer Research (AACR)
2021年博士毕业于日本金泽大学癌症研究所，医学专业，主要从事细胞周期与肿瘤发生；肿瘤联合治疗新靶点的鉴定及临床转化研究。先后获得日本学政育志赏提名、日本金泽大学高安赏、校长赏、中国国家留学基金管理委员会颁发2021年度国家优秀自费留学生奖学金B类。目前已在Hepatology等发表论文，作为项目负责人主持国家自然科学基金项目1项，上海市科委项目1项，同济大学附属妇产科医院院级课题项目1项，作为骨干成员参与科技创新2030课题3。获得3项国内药物发明专利（202310374305.8，202311658341.3，202310374279.9），1项日本药物发明专利（特願2020-180429）。2024年1月至今，在美国哈佛大学医学院Dana-Farber Cancer Institute做访问学者，继续从事细胞周期与肿瘤的发生相关研究。
Graduated with a Ph.D. in Medicine from the Cancer Research Institute of Kanazawa University, Japan, in 2021. My research primarily focuses on the relationship between the cell cycle and tumorigenesis, progression, and drug resistance, as well as identifying new targets for combination cancer therapy and their clinical translation. I have been nominated for the Japan Society for the Promotion of Science (JSPS) Prize and awarded the Takayasu Prize and the President’s Prize from Kanazawa University, as well as the National Outstanding Self-Funded International Student Scholarship (Category B) by the China Scholarship Council in 2021.
I have published papers in journals such as Hepatology and have served as the principal investigator for one National Natural Science Foundation of China (NSFC) project, one Shanghai Municipal Science and Technology Commission project, and one hospital-level project at the Obstetrics and Gynecology Hospital of Tongji University. Participated as a key member in three projects under the Science and Technology Innovation 2030 initiative. I have been granted three domestic drug invention patents (202310374305.8, 202311658341.3, 202310374279.9) and one Japanese drug invention patent (JP 2020-180429). Since January 2024, I have been a visiting scholar at the Dana-Farber Cancer Institute, Harvard Medical School, where I continue researching the cell cycle and its relationship to tumorigenesis.
Publications：
(1) Jindan Sheng; Susumu Kohno; Nobuhiro Okada; Nobuyuki Okahashi; Kana Teranishi; Fumio Matsuda; Hiroshi Shimizu; Paing Linn; Naoko Nagatani; Minako Yamamura; Kenichi Harada; Shin-ichi Horike; Hiroshi Inoue; Seiji Yano; Sharad Kumar; Shunsuke Kitajima; Itsuki Ajioka; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, HEPATOLOGY, 2021, 74(4): 1971-1993.
(2) Paing Linn; Susumu Kohno; Jindan Sheng; Nilakshi Kulathunga; Hai Yu; Zhiheng Zhang; Dominic Voon; Yoshihiro Watanabe; Chiaki Takahashi ; Targeting RB1 Loss in Cancers, cancers, 2021, 13(15): 3737.
(3) Mingjun Ma; Chao Wang; Meixuan Wu; Sijia Gu; Jiani Yang; Yue Zhang; Shanshan Cheng; Shilin Xu; Minghai Zhang; Yongsong Wu; Yaqian Zhao; Xiu Tian; Dominic Chih-Cheng Voon; Chiaki Takahashi; Jindan Sheng; Yu Wang; CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1, Cellular Oncology, 2023, 903(9): 13402.
(4) Xiaomei Luo; Yingjie Wang; Hao Zhang; Guangquan Chen; Jindan Sheng; Xiu Tian; Renhao Xue; Yu Wang; Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9, Biomolecules, 2023, 13(12): 1724.
(5) Jiani Yang; Chao Wang; Yue Zhang; Shanshan Cheng; Meixuan Wu; Sijia Gu; Shilin Xu; Yongsong Wu; Jindan Sheng; Dominic Chih-Cheng Voon; Yu Wang; Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancer, Cancer Cell International, 2023, 23(1):232.
(6) Meixuan Wu, Sijia Gu, Jiani Yang, Yaqian Zhao, Jindan Sheng, Shanshan Cheng, Shilin Xu, Yongsong Wu, Mingjun Ma, Xiaomei Luo, Hao Zhang, Yu Wang, Aimin Zhao; Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer, BMC Cancer,2024,24(1):267.
